July 17, 2025

Hormone Therapy Type Tied to Diverging Risks of Breast Cancer Before Age 55

Researchers found that unopposed estrogen therapy was linked to reduced young-onset breast cancer risk, while estrogen plus progestin therapy increased risk in certain subgroups.

Conexiant

July 16, 2025

New Guidelines Target Preventive Gaps in Inflammatory Bowel Disease

New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.

Conexiant

July 14, 2025

Can Planned C-Sections Increase the Risk of Childhood ALL?

A study that included nearly 2.5 million children born in Sweden found the risk of ALL was 21% higher in children born by planned cesarean section (C-section) compared with children born vaginally, al...

The ASCO Post

July 11, 2025

Delayed Breast Cancer Care Triples Death Risk

Delays longer than 90 days before seeking care for breast cancer were linked to a threefold increase in two-year mortality, particularly affecting older and socially isolated patients, according to a multicenter Spanish study.

Conexiant

July 10, 2025

HHS Scraps Preventive Care Panel Meeting

HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.

Conexiant

July 08, 2025

Higher BMI, Heart Disease Raise Cancer Risk 

Obesity raises breast cancer risk more sharply in postmenopausal women with heart disease, per data from 168,000+ women in two major European cohorts.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed b...

The ASCO Post